newsfilter
← Latest News
GlobeNewswire·

Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases

The Company's superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readout will be a focus of the KOL event Los Gatos, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE)